Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Cosmo Pharma plans to release Breezula, a hair loss treatment, with expected FDA approval in 2027, but concerns arise over its high potential cost of $225/month. Users express skepticism about its effectiveness compared to cheaper alternatives like finasteride and minoxidil.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

Clascoterone won't be available in the US until 2028, with EU filings planned for 2027. It's considered an alternative for those who experience side effects from standard treatments like finasteride and dutasteride.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

Veradermics has a market cap over a billion dollars, comparable to Cosmo pharmaceutical. Users discuss using Kintor's Pirylutamide for hair loss.

Several new hair loss treatments are in development, with Cosmo Breezula and Kintor KX826 being the furthest along, expected to be commercialized by 2027. Veradermics is the only treatment in pill form, while others like KX/GT/Breezula will be topical.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

Clascoterone 5% solution showed a 539% improvement in hair count compared to placebo, but the actual increase in hair growth is minimal. Users express skepticism about the effectiveness of hair loss treatments.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

Clascoterone is being discussed as a promising new hair loss treatment, showing significant improvement in trials. Despite this, skepticism persists about its effectiveness, cost, and side effects, with some users preferring minoxidil and finasteride.

Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.

A new treatment, clascoterone 5% solution, shows significant improvement in male hair loss but is considered expensive and only slightly effective by some. It has no side effects and may influence market competition.

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

A new "third cell" discovery in Japan could be key to fully regenerating hair follicles, with human trials possibly starting in 2027-2028. AI is expected to accelerate medical discoveries, potentially leading to a hair loss cure within a few years.

Clascoterone 5% solution (Breezula) is a promising alternative for androgenetic alopecia, showing continued hair growth with consistent use and no significant side effects. It may be suitable for those who cannot tolerate finasteride or dutasteride, especially when trying to conceive.

Breezula's phase 3 enrollment for hair loss treatment is complete, but results have not been published, causing skepticism about its progress. Some users express doubt about its future, suggesting it may be reserved for exclusive use.

Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

Women experienced severe reactions, including Topical Steroid Withdrawal (TSW), from using Winlevi (Clascoterone 1%) on their faces. Concerns were raised about the potential risks of higher concentrations, especially for hair loss treatment.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.

The conversation humorously discusses hair loss and potential treatments like finasteride and minoxidil. It includes playful banter and jokes about appearance and identity.

Fin and minoxidil, in combination with dermarolling, as an effective path for hair growth. The post also provides advice about needle depth and frequency, as well as other treatments (foam and oral) which may be beneficial.

Clascoterone is nearing regulatory submission as a potential new treatment for androgenetic alopecia, with positive Phase III results, while discussions continue about other treatments like PP405, minoxidil, and finasteride. Some users express excitement for clascoterone and Breezula, despite concerns about the effectiveness and practicality of topical treatments.

Minoxidil and finasteride are the only FDA-approved treatments for androgenetic alopecia, while newer treatments like clascoterone, PP405, NV-623/624, AMP-303, and RU58841 are still experimental with varying levels of evidence. Clascoterone shows the most promise due to strong human data, while AMP-303 has notable early human trial results; RU58841 lacks human data and remains experimental.